Teva and Medincell announced FDA acceptance of their sNDA for UZEDY, a risperidone extended-release injectable, to treat adults with bipolar I disorder.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

Mepolizumab led to greater symptom score improvements than omalizumab in severe CRSwNP, though both biologics showed significant nasal polyp reduction.

In this quiz, we examine your knowledge of biologic therapy for the treatment of CRSwNP.

Positive 2-year results from the open-label compensated MASH cirrhosis arm of the MAESTRO-NAFLD-1 trial highlight resmetirom’s impact on liver stiffness.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.

In this Diabetes Dialogue segment, hosts discussed the strengths of trial diversity and HbA1c reductions with automated insulin delivery in type 2 diabetes.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

A novel fast-track protocol was linked to a lower incidence of delirium and reduced LOS after transplant without increasing rejection and readmission risk.

A new study presented at AAAAI 2025 linked pediatric obesity to a greater risk of developing allergic rhinitis, with a 1.24x increased risk at 1 year.

In this quiz, we test your knowledge of evidence-based use of intranasal corticosteroids for patients with CRSwNP.

The regulatory agency has set a PDUFA target action date of August 27, 2025, for the investigational gene therapy.

In this analysis, investigators sought evaluate the effectiveness and safety of adding low-dose oral minoxidil to the standard anti-inflammatory treatment of lichen planopilaris.

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.

Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure that would eliminate ongoing disease management needs and allow greater life flexibility.

Panelists discuss how they maintain treatment adherence through digital health apps, calendar reminders, and symptom journals while working closely with their care teams to address uncertainties and make informed decisions about therapy adjustments, with crucial support from caregivers who help track appointments and provide emotional encouragement throughout their chronic care journey.

Panelists discuss how they navigated initial treatment confusion by seeking clarification from healthcare providers, consulting patient resources, and connecting with support groups to better understand their care journey.

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Despite decreasing death rates, an analysis of GBD 2021 data highlights the increasing incidence of cirrhosis and other chronic liver diseases.

Afif El-Hasan, MD of Kaiser Permanente in California joins host Albert Rizzo, MD, to discuss the acute effects of wildfire smoke on air quality.

Three subgroup analyses of the phase 3 NAVIGATOR study are set to be presented at the AAAAI/WAO Joint Congress.

Phase 3 ANCHOR-1/2 data support depemokimab as a twice-yearly treatment for CRSwNP, effectively reducing blood eosinophil counts over 52 weeks.